Loading…
As of 9 Nov 2026: SUVEN ₹279.95 (m-cap ₹7,923 Cr) vs Vimta Labs ₹504.50 (m-cap ₹2,255 Cr, P/E 28.2). Compare ROE, ROCE, growth, debt, dividends and 1-year returns.
As of · NSE prices; ratios from company filings
| Metric | SUVEN | Vimta Labs |
|---|---|---|
| Share price | ₹279.95 | ₹504.50 |
| Day change | +2.06% | −0.44% |
| Market cap | ₹7,923 Cr | ₹2,255 Cr |
| P/EPrice ÷ trailing 12-month earnings per share; blank for a loss. | — | 28.2 |
| P/BPrice ÷ book value per share. | 12.5 | 4.9 |
| ROEReturn on equity. | -81.6% | 18.9% |
| ROCEReturn on capital employed. | -80.1% | 25.0% |
| Sales growth (3Y CAGR) | -19.3% | 8.9% |
| Profit growth (3Y CAGR) | — | 18.6% |
| Debt to equity | 0.03 | 0.01 |
| Dividend yield | 0.00% | 0.40% |
| 1-year price return | +47.6% | −23.3% |
| Promoter holding | 65.5% | 35.7% |
| Industry | Healthcare Research, Analytics & Technology | Healthcare Research, Analytics & Technology |
Open in the compare tool for price charts from one month to five years, scorecards and more companies.
Each line states which company has the higher or lower figure; none of them is a recommendation.
Suven Life Sciences Ltd is larger, with a market cap of ₹7,923 Cr against ₹2,255 Cr for Vimta Labs Ltd as of 9 Nov 2026 — about 3.5 times the size.
Suven Life Sciences Ltd has no meaningful P/E right now (a loss over the last twelve months, or no reported earnings), so the two cannot be compared on P/E.
Jivani Markets does not give buy, sell or hold recommendations and is not a SEBI-registered investment adviser or research analyst. The table on this page lays out the facts side by side — price, valuation, returns on capital, growth, debt, dividends and promoter holding — so you can weigh them against your own goals, or with a SEBI-registered adviser.
Prices refresh every few minutes during market hours (delayed by up to 15 minutes) and ratios update when the companies report results. Each number is the same one shown on the two stock pages.